Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 3/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL526022 | 1.00 | CYP1A2 (0.37) | CYP1A2RENMETAP1CTSKMETAP2 | |
| SCHEMBL15858469 | 1.00 | CYP1A2 (0.37) | CYP1A2RENMETAP1CTSKMETAP2 | |
| SCHEMBL612657 | 1.00 | CYP1A2 (0.37) | CYP1A2RENMETAP1CTSKMETAP2 | |
| SCHEMBL12204090 | 1.00 | CYP1A2 (0.37) | CYP1A2RENMETAP1CTSKMETAP2 | |
| SCHEMBL3901737 | 0.97 | — | — | |
| SCHEMBL12262022 | 0.97 | — | — | |
| SCHEMBL525855 | 0.97 | — | — | |
| SCHEMBL21765542 | 0.92 | — | — | |
| SCHEMBL525786 | 0.92 | — | — | |
| SCHEMBL14615992 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230220000-A1 | PROCESS FOR PREPARING A GLP-1/GLUCAGON DUAL AGONIST | ELI LILLY AND COMPANY | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230220000-A1 | PROCESS FOR PREPARING A GLP-1/GLUCAGON DUAL AGONIST | GLP1R, GCGR, GCG | CYP1A2 177/4885REN 1919/4885METAP1 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.